Pemigatinib is an orally active, selective inhibitor of FGFR(IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively).

In cells expressing FGFR2-CLIP1 fusion are sensitive to Pemigatinib (INCB054828; IC50 value of 10.16 nM)[3].

1513857-77-6

C24H27F2N5O4

487.5

INCB054828;Pemigatinib

[1]Arudra K, et al. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018 Oct;45(10):786-790. [2]Roskoski R Jr, et al. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol Res. 2020 Jan;151:104567. [3]Krook MA, et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4).

[1]Lidsky M E, Wang Z, Lu M, et al. Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies. npj Precision Oncology. 2022, 6(1): 1-17.

DMSO:40mg/mL (82.05 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years